Chicago Research Center

Chicago, Illinois 60634

2 studies enrolling now · 28 studies all time

What they study most

Anhedonia, Depression, Depression Severe, Depressive Disorder, Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant, Depressive Episode, Depressive Symptoms, Dysthymic Disorder, Excessive Sleepiness, Fibromyalgia, Insomnia Disorders

Studies at this site

A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder — Recruiting now
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) — Recruiting now
A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure — Stopped early
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) — Running, not enrolling
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) — Stopped early
Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder — Completed
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy — Completed
A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy — Completed
A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy — Completed
A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression — Completed
A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder — Completed
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression — Completed
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD) — Completed
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients — Completed
Parallel Arm Trial of AD109 and AD504 In Patients With OSA — Completed
A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy — Completed
A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder — Stopped early
Open Label Extension for GLYX13-C-202, NCT01684163 — Stopped early
A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c — Stopped early
Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients — Completed
Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - 202 — Completed
A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD) — Completed
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca — Completed
12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress — Stopped early
Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - 301 — Stopped early
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants — Completed
Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression — Completed
Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder — Completed